- Supported exchanges /
- NASDAQ /
- TRAW.NASDAQ
Traws Pharma Inc (TRAW NASDAQ) stock market data APIs
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Traws Pharma Inc Financial Data Overview
| 0.31 | |
| 0.3198 | |
| - | |
| 0.32 | |
| 0.299 | |
| 0.24-1.1 | |
| 8 851 K | |
| 25 312 K | |
| 226 K | |
| -4.8652 | |
| 1.394 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Traws Pharma Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 226 K
- EBITDA -20 630 000
- Earnings Per Share -5.95
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Traws Pharma Inc Earnings via APIs
- Latest Release 2024-08-15
- EPS/Forecast NaN
Get Traws Pharma Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
